View
217
Download
2
Category
Tags:
Preview:
Citation preview
Localized initiatives & global virtual institutes
Stina GestreliusMedicon Valley AcademySweden-Denmark
April 2005
Medicon Valley
26 hospitals6 science parks14 universities
>100 medtech companies>100 biotech companies>50 pharma companiesCROs, service providers, investors36.000 employees (29’+7’)60 % of DK+S bio/med. exports
3.2 million inhabitants140.000 students6.000 bio-R&D
*Copenhagen University (35,000 students)*Danish Technical University*Danish Pharmaceutical University*Danish Veterinary & Agricultural University*Roskilde University CenterCopenhagen Business SchoolCopenhagen IT UniversityDanish Educational UniversityDanish Library UniversityDanish Arts and Architecture School
*Lund University (35,000 students)*Malmö University College*Swedish Agricultural UniversityKristianstad University College
* Denotes bio/med/tech research
Universities in Øresund Region
Number of publications and citations in biotech (1997-2001)
PublicationsCitationsBoston 37,000 185,000Bay Area (US) 27,500 140,000Paris 27,000 85,000Medicon Valley 15,000 52,000Cambridge area 15,000 51,000 Stockholm 14,000 49,000Munich 12,000 25,000
.
The Boston Consulting Group, 2002
Medicon Valley
0
500
1000
1500
2000
2500
3000
3500
1997 1998 1999 2000 2001 2002
Year
SC
I pa
pe
rs
MV KL
SU OX
Strategic Report
Number of biotech publications
Karolinska Institutet
Stanford
Oxford
City University of London, 2004
Scientific Excellence•Diabetes •Neuroscience •Oncology•Inflammation•Infection control
•Stemcell research•Nanotechnology•Proteomics
Medicon Valley
Blockbusters
Cipramil (antidepressive)
Lundbeck
NovoPen (insulin)
Novo Nordisk
Turbuhaler (powder inhalator)
AstraZeneca, Lund
Research infrastructure investments
•BMC (Lund)
Bio Medical Center
•CRC (Malmö)
Clinical Research Center
•BRIC (Copenhagen)
Biotech Research and Innovation Center
Total investments 3-4 billion SEK
• SWEGENE (Lund)Postgenomic RT Programme in South Western Sweden
Proteomics
Microarray
Cryo-EM
Genomic EcologyUniversity Hospital
BMC
IdeonSciencePark
MAX-lab
Transgenic core facility
Bioinformatics
Chemical Centre
LTH
Sony Ericsson
Gambro
Active Biotech
Astra Zeneca
500 m
School of Economics
LUND North Campus AreaESS?
SymbionScience ParkCopenhagen*85 enterprises in Symbion (+BRIC)*Main competences are IT and Biotechnology Bio: ACADIA, AH Diagnostics, Astion, A-Syntese, BioMonitor, Cartificial, Chempaq, Ciphergen, CMC, Colotech, CopyGene, Direct Haler, ENKAM, Evolva, Genesto, HemeBiotech, KLIFO, Leucotech, Lica, LivingCell, MedChem, NatImmune, Nordic Bone, Pipeline Biotech, Schafer, TAG, Topo
.
Medicon Valley Academy
Initiative 1995 from universitiesand big pharma companies
2000: Private membership basednon profit organisation Universities, hospitals &companies (250 members)
2 nations – 2 systems
Founding membersLU: Per Belfrage (chair)KU: Søren BuusSkåne: Ingvar WibergK Amt: Joost NielsenH:S: Helle UlrichsenFredr Amt: Anders Kyst
ElectedMikael Ørum, Ventac PartnersSibylle Moltzen Lenz, LundbeckBørge Diderichsen, NovoNordiskLars Hedbys, SynarcLars-Erik Arvidsson, AstraZenecaCristina Glad, BioInventSven Frøkjær, DFUSøren Brunak, DTUMogens Pedersen, Coloplast
Cluster Dynamics
ConceptionFormation
GrowthMaturity
Knowledge Creation Technology Transfer
CommercialisationClusters & Networks
Industry R & D
Public & PrivateFunding
Universities &Research Institutions
Patents &Licences
Proof of ConceptTesting
Incubation/Research Parks
Venture Capital
Clinical Trials
Collaboration/Partnerships
RegulatoryApproval
Business Planning
Job Creation
IPOs /gazellesLabour MarketProduct Pipeline
Economicsof Scale
RegulatoryEnvironment
M&A Activity
IndustryPartnerships
Upstream
Midstream
Downstream
POST-DOC programme (9)•system biology•nanobiotechnology•3D-modelling of molecular structures
Cooperation between Ø-forsk, Øresund IT Academy and Medicon Valley Academy
.
Medicon Valley Academy PhD programme (12)PhD students co-financed betweencompanies and HUR/Region Skåne
• Bioinformatics • Biostatistics• Children and Diabetes• 3D-modelling of Proteins• Food versus Drugs (2)• Hospital laboratory of the future• Infectious diseases• Inflammation• IT-competent hospitals• Medical Imaging (2)• Nanobiotechnology• Neuroscience• Oncology• Point-of-care testing• Proteomics (2)• Stem cells therapeutic perspectives• Therapeutic medical devices
MVA Networks
• Biostatistics• Business & Start-ups• Cancer• Diabetes• Drug Development• Food versus Drugs• Hospital Management• Human Resources• Hepatocyte User Group• Mass Spectroscopy• Technology Transfer
Strategic Report on Research in prep.
Future research strategies and implications for Medicon ValleyCopenhagen 30 March 2005
Bertil Andersson, European Science Foundation, Strasbourg
Bruno Hansen, Danish Council for Research Policy, Copenhagen
Staffan Normark, Swedish Foundation for Strategic Research, Stockholm
Kristian Helin, Biotech Research & Innovation Center (BRIC), Copenhagen
Other: Danish governmental declaration Feb 2005 Swedish research bill March 2005Six Countries Programme ConferenceEtc.
Commercialization of public research
Medicon Valley(2002)
Karolinsk
a Institutet
(2003)
Oxford
University
(2003)
Stanford Universit
y (2002)
INPUT
Research spend per year (mill. €)
300
300
200-250
400
OUTPUT
Publications
3200
2800
1900
2000
Invention disclosures
180
100
150
315
From BioScience to New Jobs in Medicon Valley - A Medicon Valley Academy Strategic Report
1) More commercial know-how into Technology Transfer Organisations
2) Regional TTO cooperation (!)
3) Funding for Proof - of- Concept studies
4) Seed investments across Øresund (!)
5) Tax incentives for the Young Biotech Industry
From BioScience to New Jobs in Medicon Valley - A Medicon Valley Academy Strategic Report
MVA STRATEGIC REPORTS
Innovation Report 2004Recommendations to improve the competitiveness of Medicon Valley
0
5
10
15
20
25
30
1997 1998 1999 2000 2001 2002 2003 2004
New bio/med-tech companies in 2004
BioneerBKG PharmaCytotrackDanChipDermagenDermalcolEssentysMedical Prognosis InstMicromorphNeobioticsNovosenseOncore TherapeuticsPHI PicologyPlug-in MedicalProtista BiotechnologyQuantibactStratoSphere PharmaVibroSense Dynamics
Retrospective
125 new companies since 1997Alt. venture capital, survival rates, IPOs etc.
Regional Guides
Patent Guide (2003) Financing Guide (2004) Drug Development Guide (2005)
Medicon Valley AcademyØresund IT AcademyØresund Food NetworkØresund EnvironmentØresund LogisticsØresund DesignØresund Nano
Development over time95 96 97 98 99 00 01 02 03 04 05
Bio
Food
IT
Environment
De-sign
Logistics
Nano
Multimedia
InterReg projectPrep. Membership organisation
Nordic Research & Innovation
Aims for borderless systems within the Nordic countries
ScanBalt: Network of Networks
PLUS:• BioTop (Berlin)• BioMoBil (Gdansk)• Ebio (Tallinn-Tartu)• Latvia• St. Petersburg
Sunrise Valley
”I think the UK and this region are perfect partners and I would like to see even greater cooperation. I am, therefore, delighted to announce today the establishment of the UK-MVA Challenge Programme. This initiative aims to encourage and facilitate greater co-operation between the UK and the Öresund region in core biotechnology areas such as research and industry. The Challenge Programme seeks to develop world class biotechnology. ..”
Lord Sainsbury, UK Minister of Research and Innovation (Oct. 2004)
Changed dynamics
• Regional integration Denmark - Sweden Researchers/ infrastructure /tech transfer/ investments
• Sectorial integration Academia- Hospital- Industry
• Increased research funding (regional, Nordic, EC)
• Increased awareness of research & innovation
Changed dynamics
• Increased investments, seed and venture capital for start-up companies (E&Y 2004)
• New companies and knowledge intensive jobs
•Increased internationalization incl.regional exchange with the UK
• International companies established in the region (e.g. Biogen Idec)
Recommended